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MATHEMATICAL MODEL OF ETHANOL 
METABOLISM IN LIVER 
 
PARAG PANDE 
ABSTRACT 
 
 A lumped mathematical model of liver metabolism is presented to analyze the 
effect of ethanol on metabolic processes of 24 hr fasted rats. The model is developed in 
two parts. In the first part individual kinetic models for important regulatory steps in the 
liver metabolic pathways are developed and in second part transport and mass balance 
equations in the two well mixed domains: tissue and blood, are developed to calculate 
intermediate metabolite concentrations and fluxes in response to the changes in ethanol 
and lactate concentrations in the perfusion medium. Part of the model without ethanol 
metabolism has been validated and published in Chalhoub et al, 2007. The focus of this 
effort was to illustrate the effect of ethanol metabolism on gluconeogenesis from lactate. 
The kinetic models developed for phosphofructokinase and fructose 1,6 bisphosphatase 
have been independently validated with data from the literature, whereas the results of the 
comprehensive lumped model are compared with the data from Krebs et al (1969). While 
the lumped model show many important characteristics of ethanol metabolism and 
predicts the flux of glucose production in the same range, two major contradictions of the 
simulated results with experimental data are observed. These shortcomings are discussed 
with appropriate reasoning. The model presented in this thesis is expected to improve the 
understanding on the effects of ethanol metabolism and provide a practical tool to address 
alcohol related health issues. 
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CHAPTER I 
INTRODUCTION 
 
The mathematical model developed here attempts to provide a useful research tool 
for understanding and predicting key characteristics of liver metabolism. The importance 
of this effort is apparent from advantages such as quantifying intermediate metabolite 
concentrations and fluxes in response to changes in various substrate concentrations. 
Liver is one of the primary organs in vertebrates.  The human liver is constructed of 
approximately one million lobules, which essentially are the basic functioning units. Each 
of these lobules consists of a hexagonal row of hepatic cells called hepatocytes. Two of 
the major functions of liver are carbohydrate metabolism to generate energy, and removal 
of toxic components by channeling them into metabolic pathways. This is achieved 
through the metabolic reactions that take place in hepatocytes, and are controlled with a 
very complex regulation through biological catalysts (enzymes). With over a thousand of 
such metabolic reactions, each depending on number characteristics like concentration of 
substrates and other metabolic intermediates and the activity of enzyme, developing a 
model that can describe the complete in vivo behavior of liver is a challenge. 
Ethanol has a large number of physiological repercussions. Alcoholism has been 
reported as one of the leading cause for a number of health issues and diseases [35, 60, 
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61, 69]. Ethanol and its oxidation product acetaldehyde severely impair normal functions 
of hepatocytes causing hypoglycemia, and alcoholic liver diseases such as hepatitis, 
cirrhosis and fatty liver. Ethanol also affects other organs like brain, heart and kidney. 
The only way to eliminate ethanol by the body is to metabolize it in the liver [35, 60, 61, 
62]. Thus a model of liver metabolism which can also account for the effects of ethanol 
metabolism can be of significant assistance to understand and treat diseases related to 
alcohol. 
 This work has been divided in three parts based on specific aims. The primary 
objective of our group was to develop a robust and realistic mathematical model 
considering the organ as a lumped system (well mixed), validate it with the available data 
in the literature to show its predictability, and confirm its usefulness by comparing the 
response of the model to addition of ethanol with data in the literature. For this endeavor 
important requisites were: sound understanding of intricate regulations of metabolic 
processes to develop individual kinetic expressions for each important regulatory step 
(which can allow us to grasp the in vivo characteristics in the comprehensive model), 
transport kinetics for each metabolite between blood and tissue, and the dynamic mass 
balances to predict the changes in concentrations and fluxes of metabolites with respect 
to time.  
Consequently, the first part of the thesis develops the kinetic expression for 
phosphofructokinase and fructose 1,6-bisphosphatase, which catalyze two of the most 
important regulatory steps in the glycolytic and gluconeogenic pathways. The second part 
describes the selection of the kinetic expressions for alcohol and aldehyde dehydrogenase 
which are the ethanol metabolizing enzymes. The third part incorporates these kinetic 
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models along with the complementary expressions for transport into a lumped model 
which can account for the effects of ethanol metabolism.  
 In this work, the mechanistic kinetic expressions presented in the first two parts 
are the quantitative description of enzyme regulation and function, in different hormonal 
and nutritional states with high degree of generality. The lumped model developed with 
the help of these expressions, along with the transport kinetics and mass balances 
presents a promising tool for understanding and predicting fundamental processes in 
metabolic system. Finally the investigation of the effect of ethanol on gluconeogenesis 
demonstrates credibility of the model in physiological context. Successful comprehensive 
models to this level of detail have not been formulated to date, which makes this a 
distinguishing effort with a very worthwhile goal. 
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CHAPTER II  
BACKGROUND 
 
2.1 Mechanism of Ethanol Metabolism 
Ethanol is an aliphatic (open chain) compound with low molecular weight. It is 
completely soluble in water via the formation of intermolecular hydrogen bonds with the 
hydroxyl groups of water. As a result of this complete solubility in water, ethanol can be 
readily distributed throughout the body, crossing important biological membranes, such 
as the blood brain barrier, to affect a large number of organs and biological processes 
[66]. Ethanol is not known to be formed in the mammalian body nor it is present in any 
of the natural food sources, therefore strong metabolic processes involving allosteric or 
back regulation (such as for lactate, glucose) are absent [37, 39].  
Ethanol taken via oral ingestion passes through the esophagus into the stomach 
and small intestine, where it is absorbed into the bloodstream (approximately 20% from 
stomach and 80% from small intestine). A very small fraction of ethanol can be 
eliminated through lungs and kidneys. Since ethanol cannot be stored in the body, it must 
be metabolized to be eliminated. Alcohol can only be metabolized in the liver, where 
enzymes are found to initiate the process [36, 37, 45, 60]. Two pathways of ethanol 
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metabolism have been extensively studied in literature, (i) through the reactions catalyzed 
by alcohol dehydrogenase (ADH) and (ii) through the Microsomal Ethanol Oxidizing 
System (MEOS) [60, 61].  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Possible metabolic pathways of ethanol metabolism [66].   
 
A number of papers are published in the literature dealing with MEOS [60, 61, 
62, 63, 64]. These papers can be divided in two groups: those where the ethanol oxidation 
is believed to occur due to the unique enzyme system involving Cytochrome P450 
(CYP2E1)[61, 63], and those which support the findings that the predominant mechanism 
for ethanol metabolism is NADPH dependent hydrogen peroxide (H2O2) production (by 
the microsomal electron transport) followed by the peroxidation of alcohol to 
acetaldehyde by catalase[60, 62].  These mechanisms are shown in Figure 1. However, 
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whether any of these systems functions in vivo or only in perfused organs, and the extent 
of their contribution in total ethanol elimination is highly controversial. The MEOS 
system consisting either of Cytochrome P450 or catalase is not inhibited by pyrazole, 
which is a strong, competitive inhibitor of alcohol dehydrogenase. Inhibition studies of 
alcohol dehydrogenase show a negligible rate of ethanol removal in liver for in vivo 
conditions [36, 60, 61].  Also some of the findings strongly suggest that the generation of 
reducing equivalence from alcohol dehydrogenation inhibits H2O2 generation leading to 
significantly diminished rates of ethanol peroxidation via catalase [62]. Under the 
conditions of chronic and high dosage of ethanol, catalase may play a small role, but even 
under these circumstances the rate of removal of ethanol is very low as compared to that 
of alcohol dehydrogenase. The reaction catalyzed by alcohol dehydrogenase (ADH) is 
still considered the primary and most important pathway for ethanol metabolism. The 
scope of this thesis is limited to the analysis of only this pathway for ethanol metabolism. 
Important regulatory steps considered in the model are shown in Figure 2.  
2.2 Effects of Ethanol Metabolism 
Irrespective of the mechanism, ethanol is converted to acetaldehyde in liver, which 
is then oxidized by aldehyde dehydrgenase (ALDH) to acetate. A fraction of acetate is 
converted to acetyl CoA while more than 60% of acetate diffuses back into the 
bloodstream [69]. The reactions catalyzed by ADH and ALDH each convert one NAD
+
 
to one NADH, producing a significant imbalance in redox ratios, which disturbs a large 
number of metabolic processes. The excess NADH affects the lactate to pyruvate ratios, 
driving the equilibrium reaction towards lactate. Thus more pyruvate goes to lactate, 
 which results in low gluconeogenic fluxes [35, 39, 40, 51, 53].
shown in Figure 2. 
Figure 2. Metabolic pathways showing 
model of ethanol metabolism.
 
Other major effects include triglyceride accumulation
in alcoholic liver cirrhosis. Excess NADH stimulates 
glycolytic intermediates. Acetyl CoA accumulation increases 
production. High NADH concentration also inhibits enzymes of the TCA cycle, further 
deteriorating metabolic functions. Acetaldehyde not converted to acetic acid can bind to 
cysteine, a constituent of the anti
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important regulatory steps in the comprehensive 
 
  
, which subsequently results 
the synthesis of glycerol from 
the rate of ketone bod
-oxidant peptide glutathione (GSH) which further 
 
ies 
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compromises liver mitochondrial functions with oxidative damage. Acetaldehyde 
released into the bloodstream can drift to other organs like brain, where it can damage 
proteins and DNA synthesis as well as lipid peroxidation in cell membranes [56, 66].   
The aim of this thesis is to show the  quantitatively effects of ethanol metabolism on 
lactate to pyruvate ratio and gluconeogenic fluxe. 
2.3 Previous Models of Ethanol Metabolism 
A number of pharmacokinetic models of ethanol metabolism are described to 
contribute to the understanding of ethanol clearance in human beings. Most of these fail 
to account for acetaldehyde, which is an important toxic metabolite of ethanol 
metabolism [41, 43, 44]. Fogler [45] presented a well-recognized, physiologically-based 
pharmacokinetic model for ethanol and acetaldehyde metabolism. The model is highly 
impressive in terms of their approach for modeling and compartmentation in which liver 
is considered as tubular reactor while the stomach, gastrointestinal tract, central fluid, and 
muscle are considered as well-stirred reactors. But their rate laws for alcohol 
dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH) are missing important 
characteristics such as ethanol substrate inhibition, NADH product inhibition for ADH 
and NAD
+
 control of ALDH. In all previous attempts of modeling ethanol metabolism, 
no attempts were made to quantify the effects of ethanol on glucose metabolism and 
lactate uptake.  
In contrast to our lumped modeling approach, several authors have presented 
other methodologies such as steady state flux balance analysis (FBA) in combination 
with either Fischer discriminant analysis or optimization of a presumed objective 
 9 
 
function. All these models contain reactions describing hepatic metabolism which 
provide insight into the distribution of fluxes over a range of steady states. All these 
approaches use experimental measurements of fluxes as inputs. Absence of reaction 
kinetics questions the reliability of these methodologies. A space - distributed  modeling 
approach is actually one of the best possible representation of liver metabolism, since it 
accounts for the heterogeneity in enzyme distribution, differential flow rates, and 
concentrations of metabolites across the liver. However, limited availability of 
experimental data makes it nearly impossible to develop and validate a distributed model. 
2.4 Role of PFK – FBPase Substrate Cycle 
The reactions catalyzed by phosphofructokinase-1 (PFK) and fructose 1,6 
bisphosphatase (FBPase) are the most significant step for controlling the relative rates of 
glycolysis and gluconeogenesis.  Tight control is accomplished through allosteric effects 
(effect on the enzyme by species other than the substrate or product of the reaction at a 
site other than the protein's active site) of fructose-2,6 bisphosphate (F2,6BP) and AMP 
on both enzymes, substrate inhibition of PFK by ATP, and glucagon-controlled cAMP-
dependent phosphorylation of FBPase. These complex control mechanisms prevent the 
simultaneous operation of both enzymes, which otherwise would lead to substrate cycling 
and concomitant ATP hydrolysis. 
  Numerous kinetic studies of these two enzymes have been reported [3, 4, 11, 16, 
18]. Most of these studies put emphasis on collecting in vitro kinetic data that reveal the 
complex behavior of the enzymes and describe the binding pattern of the allosteric 
activators and inhibitors. While each of these studies usually reported values for specific 
kinetic parameters based on the experimental conditions investigated, comprehensive 
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quantitative models that consider the more recent knowledge of these enzymes, which are 
necessary for a complete understanding of the coordinated regulation of the cycle, are 
lacking.  Furthermore, a realistic model should correctly predict the relative fluxes for a 
wide range of substrate and allosteric effector concentrations.  Moreover, these kinetic 
models play key roles in comprehensive in silico models of liver metabolism under 
development [33].  
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CHAPTER III  
KINETIC MODELS OF   
PHOSPHOFRUCTOKINASE AND FRUCTOSE-1,6- 
BISPHOSPHATASE 
 
3.1 Model Development 
The most complete quantitative model of the regulation of PFK and FBPase , 
consisting of  detailed kinetic descriptions of the two enzymes, was developed by 
Garfinkel before the discovery of F2,6BP and its important regulatory role  in regulation 
[18].  This work also did not include the effect of phosphorylation, which has been found 
to be important in the regulation of FBPase.   
The regulatory mechanism of PFK and early mathematical descriptions have been 
reported by several groups.  Brand and Soling [6] examined the kinetics of this enzyme 
under conditions of very low ATP concentrations at pH 8 (where it did not exhibit any 
allosterism) and calculated true Michaelis and inhibition constants based on an 
approximate ordered bi bi reaction mechanism at low product concentration.  Reinhart 
and Lardy [30] studied kinetic activity of the enzyme under near-physiological 
conditions.  Since these studies were done before the discovery of F2,6BP, their models 
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lack this potent influence.  The effect of F2,6BP was considered, along with calculation 
of the Km for fructose-6-phosphate (F6P) and substrate inhibition by ATP, in a later 
model of PFK by Reinhart [16].   However, this model did not include AMP activation 
and its synergism with F2,6BP, resulting in an unrealistically large estimation of the half 
velocity constant for F6P. 
The allosteric regulation of FBPase has been modeled by means of a three state 
binding model based upon the simple Monod equation [3].  However, no attempt was 
made to compute the values for the parameters of the model.  Francois et al. [4] also 
proposed a model to describe the binding pattern of rat liver FBPase, but again the 
parameter values were not computed.  
The objective of the work presented here is to develop model equations that 
exhibit the most important regulatory characteristics known of the two enzymes, PFK and 
FBPase. These equations build upon previous models, especially that of Garfinkel, and 
incorporate up-to-date information about the enzymes. Model parameters are calculated 
using data from in vitro kinetic studies. With these comprehensive kinetic models, 
simulations are performed to investigate and quantify the effects of various regulators on 
cycling and net throughput through the F6P – F16BP system, and thus to better 
understand the control mechanism for glycolysis and gluconeogenesis. Furthermore, 
these kinetic expressions play key roles in our model of gluconeogenesis and lipid 
metabolism in the liver.  
3.1.1 Phosphofructokinase 
PFK is subjected to strong metabolic control by a number of positive and negative 
effectors that include fructose 1,6 bis-phosphate (F1,6BP), F2,6BP, AMP, MgATP, H
+
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and citrate. With detailed literature review we identified important kinetic characteristics 
of PFK: 1) substrate inhibition of PFK by the high concentration of ATP; 2) activation by 
F2,6BP; 3) activation by AMP; 4) interrelation between activation of PFK by F2,6BP and 
AMP; 5) the fact that F2,6BP and AMP relives the inhibition of the enzyme by high 
concentration of  ATP [1, 2, 4, 11, 12]. These regulations are shown in Figure 3.  
Glucose
F6P F1,6BP
PEP
Protein 
Phosphatase
Active F2,6BPase
Inactive PFK-2
Protein 
Kinase
Inactive F2,6BPas
Active PFK-2
cAMP
ADP
ATP
Pi
H2O
F2,6BP
PFK-1
F1,6BPase
H2O Pi
ATP ADP
ATP ADP
H2O Pi
-
+
+
-
AMP
-
+
 Figure 3 Regulation of PFK – FBPase substrate cycle with the bifunctional enzyme 
 
Kinetic data suggested an ordered bi- bi reaction mechanism, with F6P as the first 
substrate to attach, followed by ATP (which is an inhibitor as well), and ADP as the first 
product to be released, followed by F1,6BP [6]. Since the products of the PFK reaction, 
F1,6BP and ADP, play only a minor role in deciding the rate of reaction [1], we started 
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with the approximat ordered bi-bi reaction mechanism at low product concentrations 
assuming rapid equilibrium [15]:  
 

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      (3.1) 
Simplifying this expression further we proposed:   
[ ]
[ ]PFATPK
PFATP
V
V
6][
6][
max
⋅+
⋅
=                                                     (3.2) 
PFK has low affinity and high degree of cooperativity for its substrate F6P in the 
absence of any effecter [6], based on this fact we raised F6P to the 2
nd
 power as shown in 
equation (3.3). 
  [ ]
[ ]2
2
6][
6][
max
PFATPK
PFATP
V
V
⋅+
⋅
=                                                     (3.3) 
To enforce further regulation of substrate inhibition by ATP and activation by 
F2,6BP and AMP, we modified the kinetic constant K in equation (3.3). The substrate 
inhibition can be represented by a classical expression with assumption of rapid 
equilibrium as [15]:
 
 



 


                                                        (3.4) 
 Using this equation for ATP substrate inhibition we modified the K of equation 
(3.3). The complete substrate inhibition term of ATP, in equation (3.5) is raised to the 2
nd
 
power to increase sensitivity of relative velocity of reaction to the high concentration of 
ATP, resulting in: 
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[ ]
2
2
6 ][








++=
iATP
K
ATP
ATP
KATPKK appPF
                                         (3.5) 
We selected equation used by Reinhart et al [16] to represent activation of the 
enzyme PFK by F2,6BP and AMP concentrations. These equations are shown as terms T1 
and T2 in equation (3.6) and (3.7). These terms, T1 and T2 are raised to the power n1 and 
n2 respectively, to alter the sensitivity of activation by F2,6BP and AMP. Thus at high 
F2,6BP concentration T1 à α/Q1 and at low F2,6BP concentration T1à α. Similarly at 
low ATP concentration T2 à σ and at high AMP concentration T2 à σ/Q2. In these 
expressions, α and σ are the extra binding constants and Q1 and Q2 are the coupling 
parameters which describe the nature and magnitude of the effects of each allosteric 
ligand on the binding of substrate F6P to enzyme.  If Q < 1 the allosteric ligand is an 
inhibitor, if Q > 1 the allosteric ligand is an activator, and if Q = 1 then the allosteric 
ligand has no effect on substrate binding [16]. The dissociation constant for F2,6BP and 
AMP in the absence of F6P is represented by  KiF2,6BP  and KiAMP  respectively[16].    
[ ]
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]6,2[
n1
16,2
6,2
1 

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BPFQK
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+
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AMPQK
AMPK
T
iAMP
iAMPσ                                                 (3.7) 
 
F2,6BP is the most potent activator with a complex regulatory pattern. F2,6BP 
(more prominently than AMP) relieves the substrate inhibition of ATP; this can be 
described by the product of terms T1
 
 and [ATP]
2
/KiATP.  F2,6BP increases the affinity of 
F6P for the enzyme,  but has no effect on maximal activity of PFK. F2,6BP and AMP 
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both individually and together overcome the inhibition by high concentration of ATP, 
which can be achieved with the separate term (1 + T1
 
+ T2). F2,6BP acts synergistically 
with AMP to relieve ATP inhibition thus potentiating activation by AMP [9]. Both AMP 
and F2,6BP act synergistically to decrease the half velocity constant for substrate F6P. To 
account for all these effects we proposed an equation for half velocity constant K as: 
[ ] ( )  1][ 12
2
2
16 TT
iATP
K
ATP
T
ATP
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



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


++=                      (3.8) 
The effect of phosphorylation on the kinetic properties of PFK is still an open 
question [29], and has not been considered here. The influences of citrate, F1,6BP, and 
ADP are also neglected since these interactions are less significant as compared to those 
of ATP, AMP, and F2,6BP [1, 2, 16]. The complete model is shown in expression (3.9) 
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3.1.2 Fructose-1,6-Bisphosphatase 
F2,6BP, a known powerful activator of PFK, is a strong inhibitor of FBPase. The 
main characteristics of the enzyme are: the inhibition is much stronger at low substrate 
concentration; inhibition of the enzyme by AMP is enhanced by F2,6BP (indicating 
allosteric type inhibition), and F2,6BP changes the substrate saturation curve from almost 
hyperbolic to sigmoidal [2,5,9,29]. Meek and Nimmo [3] have shown that F2,6BP can 
bind at two distinct sites, catalytic and regulatory, and at high concentration of F2,6BP in 
combination with high concentration of AMP, the kinetic response of the enzyme to 
F1,6BP reverts to hyperbolic. Further they mentioned that inhibition of FBPase by AMP 
is uncompetitive with respect to F1,6BP in the absence of F2,6BP, but non-competitive in 
its presence. However, others [5,7] have shown that F2,6BP binds only to the catalytic 
site with higher affinity than F1,6BP, which brings about a conformational change in the 
enzyme that facilitates AMP binding. FBPase is also regulated by ADP and ATP, but 
much higher concentrations of these nucleotides is needed than of AMP for a similar 
effect [7].  
The influence of phosphorylation on the activity of F1,6BPase has been a subject 
of some dispute. Some groups have observed essentially no change in the activity of the 
enzyme with phosphorylation [8,9], while others have detected increase in Vmax, and 
decrease in apparent Km for substrate with phosphorylation [7,20]. FBPase is known to 
be phosphorylated in vitro by cAMP-dependent protein kinase. It has been shown that the 
unphosphorylated FBPase is more susceptible to inhibition by AMP and F2,6BP than is 
the phosphorylated F1,6BPase [7,20]. In our model we accounted for the effect of 
phosphorylation on the enzyme by considering the variations in the cAMP 
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concentrations. The rat liver in vivo cAMP level is expected to vary from 0.008 mM in 
fasted state to 0.0012 mM in the fed state [34].  
Classical Monod, Wyman, and Changeux transition model (MWC Model) is 
considered as the basis for developing this model for FBPase because of its ability to deal 
with allosteric interactions and phosphosrylation [15]: 
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)! 
where α = [s]/Ks, the substrate concentration to kinetic constant ratio,                                               
 
The number of enzyme subunits, containing one catalytic site each, is 
approximately represented by n.  L is the allosteric constant – the equilibrium constant of 
the free form of the low substrate affinity conformation of the enzyme (T-state) and the 
high substrate affinity conformation (R-state). 
The MWC model shown in equation (3.10) is then modified by introducing 
additional terms for cAMP, AMP and F2,6BP:   
iAMPicAMPBP,iFBP,sF
c
K
[AMP]
,
K
AMP][
,
K
[F2,6BP]
,
K
[F1,6BP]
6261
==== σγβα  
In the absence of the inhibitors F2,6BP and AMP, phosphorylattion does not 
affect Vmax of FBPase but in the presence of either of the inhibitors Vmax of FBPase is 
appreciably different [7,20]. To account for this effect, the term is proposed as a 
multiplier of Vmax in equation (3.10)  
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=                                                               (3.11) 
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Both inhibitors F2,6BP and AMP act synergistically, with F2,6BP enhancing the 
effect of AMP inhibition, This effect is represented by the product of the terms (1+ β ) 
and (1+σ) for F2,6BP and AMP in the denominator of ( )σγβγ ++1  term.  
 F2,6BP is a competitive inhibitor and hence it must be also combined with the 
allosteric constant L in the denominator of the MWC expression (3.10).  Phosphorylation 
of the enzyme by cAMP-dependent protein kinase increases the activity of the enzyme by 
decreasing its apparent Km for F1,6BP. This can be achieved by dividing the allosteric 
constant L by )1( γc+ , where the quantity c is the non-exclusive binding coefficient used 
for controlling the extent of phosphorylation by cAMP. Thus the allosteric constant L of 
the MWC expression is modified to: 
n
n
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=                                                                      (3.12) 
The final equation resulting from all these hypothetical arrangements, based on 
understanding of the FBPase kinetic characteristics is shown in equation (3.13): 
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L - Allosteric constant 
c -  Non-exclusive binding coefficient 
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The sensitivity of the activity vi of  each enzyme i,  relative to each parameter Ki,j 
in the kinetic model was defined as Svi,Ki,j, given by: 
jiji
ii
KK
vv
jKiviS
,,
,, ∂
∂
=
     (3.14)
 
The sensitivities were calculated using the central difference method, at concentrations 
representative of the fed and fasted states.  
3.2 Results 
While numerous groups have obtained kinetic data on PFK from liver, the data 
reported by Van Schaftingen et al. [1] is among the most comprehensive and includes 
effects of F2,6BP and AMP.   Moreover, their study was performed at near physiological 
concentrations of metabolites, which is important if the model expression is to be 
applicable in vivo.  The kinetic parameters for PFK were obtained by fitting Eqn. 3.9 to 
their data using the generalized reduced gradient method in microsoft excel. Parameter 
estimation for Eqn. 3.13 (FBPase) was performed using in vitro kinetic data obtained by 
Ekdahl et al. [20], with an emphasis on data obtained for physiological ranges of 
metabolites.  Estimated parameters and confidence intervals are shown in Tables I and II.  
Table I Parameter values with confidence intervals in the PFK model (Eqn. 3.9). 
 
 
 
 
 
 
 
 
α 2 +/- 1.88E+01  
σ 3.5 +/- 8.63E+01  
KATP (mM) 0.05 +/- 1.77E+00  
K
app
F6P (mM) 0.0007 +/- 1.84E-03  
KiATP (mM) 1 +/- 2.05E+01  
n1 3 +/- 2.77E+01  
n2 3 +/- 5.64E+01  
KiF2,6BP (mM) 0.03 +/- 7.74E+00  
Q1 100 +/- 2.65E+04  
KiAMP (mM) 2 +/- 3.77E+02  
Q2 50 +/- 1.04E+04  
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Table II Parameter values with confidence intervals in the FBPase model (Eqn. 3.13). 
 
KsF1,6BP uM 1 +/- 1.80e+000  
KiAMP uM 182.20 +/-  1.35e+001  
KiF2,6BP uM 30 +/-  9.23e+000  
KicAMP uM 20 +/-  6.60e+001  
L 2.76E+06 +/-  1.00e+007  
n 5.52 +/-  1.69e+000  
c 0.56         +/-   Inf  
 
 
The relative activities of PFK predicted by Eqn. (3.9) are shown in Figure 4 along 
with the data obtained from the in vitro experiments.  In general, the model captures the 
important trends of the data as well as other known regulatory effects, in terms of 
activation by F2,6BP ( Figure 4A-D), substrate inhibition by ATP (Figure 4B), activation 
by AMP (Figure 4D), and hyperbolic dependence on the two substrates at high F2,6BP 
concentrations (Figure 4A,C). At low concentrations of F2,6BP the model shows proper 
cooperative behavior of the enzyme for substrate F6P (Figure 4A) and for F2,6BP as well 
(Figure 4D).  
Figure 4B shows the expected reduction of ATP-substrate inhibition by F2,6BP.   
The synergism between activation by AMP and F2,6BP are demonstrated in Figure 4C.   
While a very good correspondence between model and data are shown for most of the 
concentration ranges, the model greatly underestimates activity at AMP greater than 0.4 
mM and F2,6BP  at 0.25 µM or less.   However, this region is at AMP concentrations 
greater than that occurring in vivo ( 0.1 – 0.3 mM) [5,12,13,17,18], and at  F2,6BP 
concentrations in the low range of in vivo concentration (0.1 to 10 µM) [16,17],  so 
analyses using this model at in vivo conditions can be presumed to be valid.  The 
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interaction of F2,6BP with AMP, at more physiological concentrations, is demonstrated 
in Figure 4D, with good correspondence between data and model.  
Simulations of FBPase activity using Eqn. (3.13) are shown in Figure 5 in 
comparison to in vitro data.  The inhibition by F2,6BP and the positive effect of 
phosphorylation are captured almost perfectly, as shown in Figure 5A, which also 
demonstrates that phosphorylation is ineffective at saturating concentrations of substrate.  
The substrate-dependency is predicted well (Figure 5A,B,C), except at the 
unphosphorylated state at high concentrations of F2,6BP, where no FBPase activity was 
measured (Figure 5C).    Since FBPase is homotetramer [3,7,8], the expected value of n is 
4, although the value that resulted in the best fit was actually  5.5, indicating that the 
MWC model is not a rigorously correct description of the mechanism.  
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Figure 4 (A) 
 
 
 
 
 
Figure 4 (B) 
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Figure 4 (C) 
 
 
 
Figure 4 (D) 
Figure 4 Simulation results for phosphofructokinase kinetic model (Eqn.3.9).The in vitro 
data used for developing the model with the corresponding model calculated outputs are 
shown in the figure. Effect of F2,6BP on the affinity of PFK for substrate F6P (A) and on 
inhibition of PFK by substrate ATP (B). Figures. (C) and (D) show effects of F2,6BP and 
AMP on relative velocity of PFK.  Simulation results are continuous lines, corresponding 
experimental data are represented as points with the same color. Other metabolite 
concentrations are as shown on the Figure. The data is from Van Schaftingen et al. [1]. 
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Figure 5. (A) 
 
 
 
 
Figure 5. (B) 
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Figure 5. (C) 
 
 
Figure 5. (D) 
 
Figure 5.  Simulation results for F1,6BPase model, Eqn. (3.13). The in vitro experimental 
data (data points) along with the model calculated outputs (continuous lines) for FBPase 
is shown in fugure. (A) Inhibition of rat liver phosphorylated and unphosphorylated 
F1,6BPase by F2,6BP at two different concentrations of F1,6BP, 33 and 12.5 µM 
respectively. (B) and (C): effects of  AMP and F2,6BP on the flux of F1,6BPase at 
different concentrations of substrate F1,6BP. (D) shows activity of phosphorylated and 
unphosphorylated enzyme at different AMP concentrations. The cAMP concentration 
used in the model results for phosphorylated enzyme is 0.0075 µmol/gww (16 µM) [34]. 
Other metabolite concentrations are as shown on the Figure The data are from Ekdahl et 
al. [20]. 
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Simulations of the fluxes through PFK and FBPase at physiological 
concentrations of metabolites, in the fed and fasted states, using Eqns (3.9) and (3.13), 
are shown in Figure 6.  Figure 6A shows the fluxes as a function of the ATP/ADP ratio, 
where the total nucleotide concentration is kept constant.  The two rates are relatively 
independent of the ATP/ADP ratio near the value of 5.9 (measured in the cytosol in the 
starved state [19]), indicating little control by this quantity at physiological conditions. As 
expected, the rate of PFK is almost completely inhibited in the fasted state, while the flux 
in the fed state is activated to 1.11 µmol/gww/min.  Conversely, the FBPase is inhibited 
in the fed state to 0.11 µmol/gww/min and activated in the fasted state to 0.89 
µmol/gww/min. The net rate of glycolysis in the fed state is close to that measured in vivo 
1.0 µmol/gww/min [ 23-27,31], with about 10 - 15 % of the carbon recycled through the 
futile cycle.  In the fasted state, the net rate of gluconeogenesis is 0.9 µmol/gww/min, 
which is approximately double that expected for an in vivo 24 hour fasted state, [32] with 
no futile cycling, which is in agreement with previous predictions [28].   These results 
were calculated with the FBPase Vmax of 16 µmol/gww/min.  The measured maximal 
activity of FBPase from liver tissue actually has a large range (16 ±7 µmol/gww/min) 
[22], which greatly influences the results obtained.  
The regulatory effects of F2,6BP and AMP on the two enzymes are shown in 
Figure 6C-D.  It can be observed in Figure 6C that high concentrations of F2,6BP 
relieves the substrate inhibition by ATP of PFK at physiological concentrations of all 
other metabolites. This is a very important property of the enzyme behavior in vivo, as 
mentioned earlier. Note that the greatest amount of futile cycling occurs in the mid-range 
of F2,6BP concentration, with little futile cycling at the two extreme concentrations of 
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F2,6BP.  Figure 6D shows the effect of AMP on the fluxes.  AMP also affects the amount 
of futile cycling, with most cycling occurring at the lowest AMP concentration.  
The sensitivities of PFK flux to the model parameters are shown in Figure 7A.  
Under fasting conditions, the flux of PFK is very sensitive to changes in α, KiF2,6BP, KiATP, 
Q1 and n1, while at the fed state the PFK flux is nearly insensitive to the same 
parameters.  Since the flux of PFK at the fasted state is negligible, the large sensitivities 
at that state have no physical significance.  Figure 7B shows that the model for FBPase is 
highly sensitive to parameters n, KiAMP, and KicAMP.   The terms in the MWC model for 
FBPase (Eqn. 3.13) are raised to the power n, leading to the high sensitivity to this 
quantity. The phosphorylation state of the enzyme strongly influences its activity, which 
affects the extent of inhibition by KiAMP and KiF2,6BP and is affected by the cAMP 
concentration relative to KicAMP. 
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Figure 6 (A) 
 
 
 
 
Figure 6 (B) 
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Figure 6 (C) 
 
 
 
Figure 6 (D) 
 
Figure 6 Simulations results for PFK and FBPase in fed and fasted states, Eqns. (3.9) and 
(3.13).Species concentrations set equal to values representative of either the in vivo fed or the 
fasted states.  Fed state [AMP] = 180 µM [5,12,13,17,18], [F1,6BP] = 46 µM, [14,16,17], 
[F2,6BP] = 10 µM,[16,17]. [F6P] =0.05 mM [14,18], [cAMP] = 1.2 µM, [34] Fasted state [AMP] 
= 380 µM,[5,12,13,17,18]. [F1,6BP] = 55 µM, [15,16,17], [F2,6BP] = 0.1 µM,[16,17], [F6P] 
=0.01 mM,[14,18] [cAMP] = 12 µM.[29]. Vmax for PFK = 3 µmol/gww/min,[21] Vmax for 
F1,6Bpase = 16  µmol/gww/min.[22]  (A) Fluxes as a function of ATP/ADP, keeping the 
nucleotide sum constant; (B) fluxes as functions of ATP, with all other concentrations constant. 
(C) Effect of different concentrations of F2,6BP on the fluxes of both the enzymes at different 
concentrations of ATP. (D) Effect of different concentrations of AMP on the fluxes of both the 
enzymes at different concentrations of ATP. Other metabolite concentrations are as shown on the 
Figure 
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Sensitivity Analysis: 
 
 
 
 
 
 
 
Figure 7  Sensitivity analysis of the kinetic constants to the relative activities of PFK 
FBPase enzymes in fed and fasted state. 
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3.3 Discussion 
 
The two model equations presented are based on the most up-to-date findings on 
the regulatory characteristics of PFK and FBPase, and result in close correspondence 
with in vitro kinetic data, especially for the conditions at the physiological concentrations 
of metabolites.  Although a lot of kinetic data on inhibition and half-velocity constants 
have been published for these enzymes, the parameters have been reported for specific 
conditions.  Quantitative models for PFK and FBPase that integrate the major kinetic 
effects, including more recent information such as the effects of F2,6BP on both enzymes 
and the phosphorylation of FBPase, are not available. After the validation of each kinetic 
equation, the model was then used to explore the effects of different regulators on the net 
flux through the system and the expected extent of substrate cycling. The calculated flux 
of gluconeogenesis is only 10% less than the experimental value in fasted state, this 
demonstrate the reliability of the model.   
 PFK – FBPase is probably the most important control site for gluconeogenesis 
and glycolysis with both short-term and long-term regulation by insulin and glucagon.  
The increase in glucagon in the fasted state activates adenylyl cyclase, which results in 
elevation of intracellular cAMP levels, which in turn activates cAMP dependent protein 
kinase. The cAMP dependent protein kinase then catalyzes phosphorylation of the 
bifunctional enzyme PFK2/F2,6Bpase and FBpase. The phosphorylation of the 
bifunctional enzyme decreases F2,6BP levels because of activation of F2,6Bpase and 
inactivation of PFK2 while the phosphorylation of FBPase later results in its increased 
activity and hence increased flux of gluconeogenesis.  The decrease in F2,6BP directly 
deactivates PFK and activates FBPase further which again results in increased flux of 
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gluconeogenesis. These changes also have a potent effect on the other substrate cycle, 
PEP – pyruvate,  since cAMP dependent protein kinase phosphorylates pyruvate kinase, 
decreasing its activity. Also the decrease in F1,6BP level because of activation of FBpase 
deactivates PK, both allostericaly ( F1,6BP is a strong activator of PK) and by making the 
enzyme better substrate for phosphorylation by cAMP dependent protein kinase.  Thus 
the F6P – F1,6BP substrate cycle operated by the two enzymes not only affects the rate of  
gluconeogenesis and glycolysis but also strongly regulates the  PEP – pyruvate cycle.  
We have accounted for the hormonal effects on PFK and FBPase through the terms for 
F2,6BP and cAMP, and although they are set independently in the equations, they are 
actually linked in vivo, as described above.   
The statistical analysis of the two models was done to compute the confidence 
intervals of the constants. These are reported in Table I and II. It can be observed that the 
upper and lower limits of the confidence intervals are very large as compared to the 
parameter values. We used two softwares: excel and matlab to calculate these confidence 
intervals. Both programs gave the same results. This indicates the existence of singularity 
which may result from interdependence of the model parameters. This means that the 
values of the constants in the two kinetic models for PFK and FBPase are not uniquely 
determined. 
 The basic aim of our effort to develop the kinetic models for these two enzymes 
was to account for a number of important in vivo regulations. This could have been 
achieved by using a complex polynomial expression that had constants with small 
confidence intervals and exactly matched experimental data. But it is important to 
recognize that the physiological significance of the model structure and parameter values 
 34 
 
is of high importance. These expressions are critical part of our comprehensive model of 
ethanol metabolism. Thus it is important to preserve the significance by keeping these 
constants near the actual in vivo range of the respective substrate concentrations. 
The model equations and parameters presented here are useful for understanding 
metabolic regulation and predicting liver cell behavior when combined with the kinetic 
descriptions of the other reactions in various pathways in the liver. A model of 
gluconeogenesis and lipid metabolism in the perfused rat liver, that includes the kinetic 
equations presented here, has been developed and shown to be predictive of the 
intermediate concentrations and fluxes in response to perfusion with lactate, pyruvate, 
and fatty acids.  The PFK-FBPase model can be further improved by introducing other 
known allosteric effectors, such as  F1,6BP, ADP, and citrate for  PFK, although we 
expect that this will have little effect on the predictive ability of the in vivo model, since 
these metabolites have a minor role in the regulation of PFK –FBPase. [1, 4, 31].  
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CHAPTER IV  
KINETIC MODELS OF ALCOHOL AND  
ALDEHYDE DEHYDROGENASE 
 
4.1 Alcohol Dehydrogenase 
The physiological role of alcohol dehydrogenase in liver has been puzzling 
because of the poor stereospecificity of the enzyme for its substrate. Alcohol 
dehydrogenase catalyzes many reactions involving different types of alcohol, farnesol 
and certain hydroxy and keto steroids. It has been suggested that oxidation of ethanol is 
only an occasional activity while the major function of alcohol dehydrogenase is to 
remove potentially toxic substrates, including ethanol, from circulation and channel them 
into the pathway of energy supply [35, 36, 37].  
As described in the first part of the thesis, in order to predict rates of ethanol 
elimination at different ethanol concentrations and under different nutritional and 
endocrinologic conditions we require knowledge of (1) total activity of alcohol 
dehydrogenase, (2) the contents and specific activity of different forms of the enzyme, if 
present, (3) kinetic mechanism and constants (i.e., the rate equation) and, (4) in vivo 
concentration of substrates and products during ethanol metabolism.  
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Kinetic behavior of alcohol dehydrogenase has been well studied and documented 
over the last few decades. The reaction catalyzed by alcohol dehydrogenase is essentially 
a cytosolic reversible reaction, involving substrates ethanol and NAD
+
 and products 
NADH and acetaldehyde [41, 42, 43]: 
 
 
 There are numerous factors which define the activity of this enzyme in vivo, 
including age, sex, genetics, and the nutritional state of the body [35]. It has been 
reported that activity of alcohol dehydrogenase falls to as low as 40% during fasting. 
Although numerous isoenzymes of alcohol dehydrogenase have been reported (grouped 
in Class I, II and III), their kinetic behavior is very similar to each other (70-90% 
homology between the classes) [50]. Therefore, in this attempt isoenzymes of alcohol 
dehydrogenase are not differentiated, and the activity of alcohol dehydrogenase is its total 
activity. Alcohol dehydrogenase is found to be inhibited by high concentrations of its 
substrate ethanol (above 10 mM) and product NADH. Factors influencing the rate of 
ethanol removal are (1) activity of alcohol dehydrogenase, (2) reoxidation of NADH, 
and., (3) NAD
+
, NADH and ethanol concentrations [42, 43, 57]. 
 
Figure 8. Ethanol metabolism with NADH reoxidation by malate – aspartate shuttle [59]. 
CH3CH2OH + NAD
+
                  CH3CHO + NADH + H
+ 
ADH 
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Activity of alcohol dehydrogenase as motioned before varies significantly with 
the nutritional state as well as during metabolism. As the alcohol dehydrogenase reaction 
starts, it drastically alters redox ratios in cytosol, as NAD
+
 becomes limiting, high 
concentrations of NADH produced must be reoxidized to NAD
+
 through the malate 
dehydrogenase shuttle which takes place in mitochondria. Studies of ethanol metabolism 
strongly suggest that these two factors, namely activity of the enzyme and reoxidation of 
NADH, are the two most important factors in controlling the rate of ethanol elimination 
[58, 59]. At high concentrations of ethanol and NADH, a ternary complex of ethanol –
ADH–NADH is formed which does not appreciably break down to an ethanol-ADH 
complex and ultimately does not transform into products [43]. Thus the ADH reaction is 
inhibited by high concentrations of ethanol and NADH. Other factors such as transport of 
ethanol from blood to tissue are not considered important because of the complete 
solubility of ethanol in water [57, 58, 59]. 
Based on these facts it can be concluded that ethanol elimination is approximately 
zeroth order with respect to substrate, with substrate inhibition of ethanol and product 
inhibition by NADH at their high concentrations. This type of behavior is best described 
by the Theorell – Chance mechanism shown in Figure 9 and equation (4.1) [41, 42]. 
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(4.1) 
 
 
where, [A] = NAD
+
    [B] = Ethanol      [P] = Acetaldehyde [Q] = NADH 
 
 
Figure 9 Schematic of the Theorell-Chance mechanism [43]. 
Table III Kinetic constants of alcohol dehydrogenase model (Eqn. 4.1) [43]. 
Michaelis Constants µmol/ghep 
Kb   480E-3 
Kq    4E-3 
Ka    33E-3 
Kp    37E-3 
Keq   1.94E-4 
MaximumVelocity  µmol/ghep/min 
Vf    6.71 
Vr    33.62 
Inhibition Constants µmol/ghep 
Kib  810E-3 
Kiq  0.9E-3 
Kia  58E-3 
Kip  12E-3 
Ki   1.7E2 
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Crabb and Bosron [43, 44] extensively studied and justified the use of the 
Theorell – Chance mechanism for alcohol dehydrogenase. Characteristics such as 
substrate and product inhibition at their high concentrations making them important 
regulators, formation of substrate-enzyme- product ternary complex, as well as dead-end 
pyrazol inhibition are consistent with the Theorell – Chance mechanism. Kinetic 
constants from the in vitro freeze clamped liver study on the fed and fasted animals are 
reported in Crabbb - Bosron [43, 44]. Predictions of the rate of ethanol elimination using 
those kinetic constants and a Theorell – Chance mechanism are found to be in agreement 
with those found in vivo and are reported in the same publication.  
Some authors have tried to describe the behavior of alcohol dehydrogenase with 
ordered bi-bi reaction mechanism, which is approximately similar to the Theorell – 
Chance mechanism, except for the last two terms in the denominator of equation (4.1) 
[49]. At low concentrations of ethanol both mechanisms yield approximately the same 
results but at high ethanol concentration (> 10 mM ), the Theorell – Chance mechanism 
shows the important characteristic of substrate inhibition, which is missing in Ordered bi-
bi reaction mechanism. For all these reasons we have selected the Theorell – Chance 
mechanism for the estimation of the rate of the alcohol dehydrogenase reaction in the 
next chapter of the thesis. 
4.2 Aldehyde Dehydrogenase 
 Unlike alcohol dehydrogenase, which has isoenzymes with identical kinetic 
constants and overall behavior (in fed and fasted states), isoenzymes of aldehyde 
dehydrogenase have a very small homology and a strong differential intracellular 
distribution between the different forms of the enzyme.  These isoenzymes of aldehyde 
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dehydrogenase are grouped into two classes based on their affinity for acetaldehyde as 
high-Km aldehyde dehydrogenase (Km > 1 mM) and low-Km aldehyde dehydrogenase (Km 
≤ 1 µM). Marjanen [42] reported that 80% of the total activity of aldehyde 
dehydrogenase is found in the mitochondria while only 20% is found in the cytosol. 
Moreover, most of the enzyme in the mitochondria is the low-Km aldehyde 
dehydrogenase and the cytosolic enzyme is high-Km aldehyde dehydrogenase. 
 The reaction catalyzed by aldehyde dehydrogenase is essentially an irreversible 
reaction involving substrates acetaldehyde and NAD
+
 and products NADH and acetate 
[45, 46, 47]: 
 
 
 The rate of acetaldehyde removal is controlled by the concentration of 
acetaldehyde, the activity of the enzyme, as well as the NAD
+
 concentration available in 
the respective intracellular compartment. At low acetaldehyde concentration, the NAD
+
 
control is weaker, since enough concentration of NAD
+
 is available for the oxidation of 
acetaldehyde. However, at high acetaldehyde concentration, NAD
+
 plays a significant 
role in controlling the flux of ALDH reaction. During ethanol metabolism only a small 
fraction of cytosolic NAD
+
 is available for acetaldehyde oxidation, since most of the 
NAD
+
 is utilized for oxidation of ethanol. Svanas and Weiner [46], as well as Williamson 
[47] reported that acetaldehyde oxidation in rat liver occurs almost entirely in 
mitochondrial compartment at low to moderate concentrations of acetaldehyde. At high 
acetaldehyde concentration, however, oxidation may take place in cytoplasm as well. 
Nevertheless, the amount of acetaldehyde oxidized in mitochondrial compartment is 
CH3CHO + H2O + NAD
+
                     CH3COOH + NADH + H
+ 
ALDH 
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always much higher than that occurring in cytoplasmic compartment; especially in case 
of acetaldehyde from ethanol metabolism.  
 Based on these facts we concluded that a simple Michaelis – Menten equation 
with some consideration to the NAD
+
 control should be enough to describe the kinetic 
behavior of aldehyde dehydrogenase. 
 
 (4.2) 
   Where S = acetaldehyde 
 
Table IV Kinetic constants of alcohol dehydrogenase model (Eqn. 4.2) [46]. 
Vmax 5.3 µmol/ghep/min 
Km_s 3.40e-04 µmol/ghep 
Km_NAD 0.00928 µmol/ghep 
 
Svanas and Weiner [46] and Fogler [45] used a simple Michaelis –Menten 
approach (rate of reaction regulated by the enzyme activity only) for estimating rates of 
acetaldehyde metabolism. Fogler proposed an unsteady state, physiologically based 
perfusion liver model to predict the rate of acetaldehyde elimination from ethanol in 
different human body compartments – stomach, GI, liver and so forth. Svanas and 
Weiner, on the other hand, used experiments with isolated mitochondria of rat 
hepatocytes and a combined expression of two Michaelis –Menten equations for the low 
and high Km acetaldehyde dehydrogenase to estimate the rate of disappearance of 
acetaldehyde. The rates calculated by Svanas and Weiner at 200 µM acetaldehyde 
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approximately matched with those found experimentally. Therefore, we used the same 
kinetic constants estimated by Svanas and Weiner with the assumption that the 
acetaldehyde is metabolized entirely in the mitochondrial compartment and that the 
concentration of NAD
+
 also regulates the rate of acetaldehyde elimination. 
4.3 Transport Mechanism for Ethanol and Acetate 
The rate expression used for net transport of ethanol, acetate and other 
metabolites such as glucose and lactate across the sinusoidal membrane is assumed to be 
facilitated transport, given by: 
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 The transport constants for expressions (4.3) and (4.4) are show in Table V. Vmax 
and Km for the transport of both ethanol and acetate are obtained from the literature by 
referring to the observed rate of ethanol and acetate elimination from blood in vivo [69].  
Table V Kinetic constants for transport expression for ethanol and acetate. 
Vmax,etoh,b_t 4.3 µmol/ghep /min From in vivo study [69] 
Km_etoh_b-t 0.1 µmol/ghep Assumed based on expected ethanol 
concentration in vivo 
Vmax,acetate,b_t 4.04 µmol/ghep/min From in vivo study [69] 
Km_acetate_b-t 0.1 µmol/ghep Assumed based on expected acetate 
concentration in vivo 
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CHAPTER V  
MATHEMATICAL MODEL OF ETHANOL METABOLISM 
IN LIVER 
 
5.1 Model Development 
The purpose of modeling individual kinetic reactions accurately in the previous 
two sections (for phosphofructokinase, fructose 1,6-bisphosphatase and alcohol and 
aldehyde dehydrogenase) was to obtain a reasonable flexibility and predictive power for 
the estimation of concentrations and fluxes through each important regulatory step. This 
is very crucial especially since significant recycling and complex regulation is involved 
in these steps. Similar type of models were developed for other important reaction steps 
like pyruvate kinase, pyruvate carboxylase and pyruvate dehydrogenase complex in our 
group. Some of the simple, irreversible reactions are expressed with Michaelis – Menten 
kinetics and introducing the ratios like ADP/ATP and NADH/NAD as relevant. With all 
this detailed kinetic modeling and in-depth research on the complex regulation of 
metabolism, we developed the basic building blocks for the lumped model of hepatic 
metabolism.  
The initial challenge was to confirm the effect of lactate and pyruvate perfusion 
on the gluconeogenic fluxes and metabolite concentrations by comparing the calculated 
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results with the experimental data available from the literature. This part of the work has 
been completed by coworkers (published in Chalhoub et al. 2007) [38]. The metabolic 
pathways considered were glycolysis, gluconeogenesis, citric acid cycle, fatty acid 
oxidation, fatty acid synthesis, ketogenesis, oxidative phosphorylation, and glycogen 
degradation, with each pathway represented by a few key reactions, as shown in Figure 2. 
Ethanol causes enormous turbulence in normal metabolic operations of hepatocytes. It 
significantly affects almost all these pathways. Thus analyzing the response of the model 
by adding the ethanol metabolism part can be used to validate the entire model, instead of 
using different substrates which can stimulate only one pathway. 
For the comprehensive lumped model of the perfused rat liver, tissue and blood 
compartments are considered as two well mixed domains with mass balances for each 
metabolite as show in equations (5.1), (5.2), (5.3). The mass balance in the tissue domain 
is given by: 
  
        (5.1) 
The mass balance in the blood domain is given by: 
 
                                                                                                                            (5.2) 
The mass balance in the perfusate is given by: 
 
 
    (5.3) 
 
Ci,perfusate - concentration of metabolite i in the perfusion medium (µmol / ghep). 
Vperfuate - volume of the perfusion medium. 
perfusateF  - perfusate flow rate through the liver.   
J i,b-t  - transport rate between the blood and tissue domains, (µmol / ghep min)  
Ri,j -  is the reaction rate of each reaction j with metabolite i as substrate or product 
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Eq (5.1) and (5.2) are written only for those metabolites which are expected to 
occur in blood (i.e. GLC, LAC, ALA, AcAc, BHB, PYR). The perfusion medium vessel 
is also considered as well mixed system. The quantities Fperfusate and Vperfusate in Eqn. (5.1) 
are assigned values that match the specific experimental conditions from the literature.  
The rate mechanism for transport between the blood and tissue domains is 
described by facilitated diffusion.  Reversible near-equilibrium reactions (e.g. RGAP
à
PEP, 
RLDH) are represented by a simplified form of a reversible, ping-pong mechanism, with 
the Haldane equation used to relate kinetic parameters values at near-equilibrium and to 
ensure consistency with thermodynamic constraints. The kinetic parameters were 
generally obtained either from in vitro kinetic studies with purified enzymes, by 
calculation from in vivo data and the assumed rate expression, or a combination of these 
methods. 
Redox ratios are significantly different in cytosolic and mitochondrial 
compartments. Accounting for this difference is extremely important especially for 
investigating effect of ethanol metabolism, since both the reactions for ethanol removal 
involves NAD
+
 and NADH as substrate and product. We tried to address this issue by 
establishing a pseudo-mitochondrial compartment for NADH/NAD
+
, with the assumption 
that the mitochondrial redox ratio, RSm (defined as CNADH(M) / CNAD
+
(M)), is in 
equilibrium with the cytosolic ratio RS (CNADH(C) / CNAD
+
(C)); this assumption is 
expressed as  RSm = Keq,RS · RS. The equilibrium constant Keq,RS is calculated from the 
ratios of free cytosolic and mitochondrial CNADH /CNAD
+
 at the fasted steady state, 
obtained from measurements of CLAC / CPYR and CBHB/CAcAc, respectively, at equilibrium 
[38, 55, 58]. 
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Chapters III and IV describe individual kinetic models for important regulatory 
steps like PFK – FBPase with their independent validation. For complete list of all the 
kinetic models used in the lumped model along with their constants, please refer the 
appendix of this thesis. 
The lumped model with ethanol metabolism thus consist a total of 66 fluxes 
which include transport and kinetics, 39 concentration terms of metabolites in blood, 
tissue and perfusate and as a result 39 ordinary differential equations for mass balances. 
The code was originally written in FORTRAN. As part of this thesis work, the code was 
converted to MatLab and the 39 mass balances were solved simultaneously using MatLab 
ordinary differential equation solver ode15s. We selected ode15s based on the 
understanding of stiffness of the system, recognized during previous simulation runs on 
FORTRAN. 
5.2 Simulation Method 
In this section results from the lumped model with infusion of ethanol metabolism 
are discussed and compared to literature data. 
Krebs [35, 36, 37] performed experiments with perfused rat liver to study the 
effect ethanol on gluconeogenesis from lactate. The data published in Krebs et al (1969) 
[35] is compared to the calculated results. In these experiments, he estimated the rate of 
glucose formation at different initial ethanol concentrations and 10 mM initial lactate as 
the recirculating single infusion.  Accordingly, we set the initial concentration of lactate 
in perfusion to 10 mM and the program was run using 6 different concentrations of 
ethanol in the perfusion medium used by Krebs, shown in Table V. The initial conditions 
used for other metabolites are shown in Table VII. These metabolite concentrations are 
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from the initial lumped model without ethanol metabolism, validated with the data 
obtained from Williamson et al [67].  
 The simulation is run over a time span of 0 to 130 min. Lactate and ethanol 
perfusion begins at time t = 0 min. A single dose (pulse) of both substrates is added over 
the entire time span. The recirculating perfusion method used is described [35]. Seven 
separate sets of initial conditions were prepared. In each data set all the metabolite 
concentrations are same except ethanol, which is increasing from 0 to 40, as used by 
Krebs in his experiments. All these seven initial conditions are simulated separately, each 
generating a comprehensive set of metabolite concentrations and fluxes with respect to 
time. For this purpose a main MatLab program is written which can accept all these 
initial conditions and run ode15s for each condition, solving 39 ordinary differential 
equations for the mass balances along with their kinetic and transport equations for each 
particular time step. A time-average over the simulated time span is calculated for all the 
fluxes, similar to the method reporting in Krebs’ paper. 
Table VI Ethanol and lactate concentrations added in perfusate for different initial 
conditions used in simulation. 
 
Experiment 
No. 
Initial Ethanol 
concentration in 
perfusion medium 
mM 
Initial lactate 
concentration in 
perfusion medium  
mM 
1 0 10 
2 1.25 10 
3 2.5 10 
4 5 10 
5 10 10 
6 20 10 
7 40 10 
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Table VII Other initial metabolite concentrations used, common to all initial conditions 
of (Table VI). 
 
Metabolite 
Concentration in  
µmol/ghep 
Metabolite 
Concentration in  
µmol/ghep 
Glcucose_blood 0.46 Alanaine _blood 0 
Glcucose_tissue 0.47 Acetoacetate_tissue 0.82 
Lactate_blood 0 BHB 0.15 
Lactate_tissue 0 Pyruvate_blood 0 
G6P 0.001 Acetoacetate _blood 0.80 
Glycogen 108.01 BHB_blood 0.14 
ATP 1.00 NH4 0.58 
NADH 0.0001 F6P 0.0006 
Pyruvate 0 F16BP 0.0007 
AcCoA 0.009 Glcucose_perfusate 0.45 
PEP 0 Acetoacetate _ perfusate 0.75 
GAP 0 BHB_ perfusate 0.14 
FFA 0.07 Etoh_blood 0 
TG_tissue 3.74 Etoh_tissue 0 
GLR_tissue 0 Acetaldehyde 0 
GR3P 0 Acetate_blood 0 
FFA_blood -0.018 Acetate_tissue 0 
GLR_blood 0.05   
TG_blood 0   
Alanaine_tissue 0.17   
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5.3 Results 
Figure 10 (A) shows the flux of the reaction catalyzed by alcohol dehydrogenase 
for the initial conditions of different ethanol concentrations as shown in the Table VI and 
VII. It can be observed that the flux decreases around ethanol concentration 10mM. This 
shows the important feature of the Theroll – Chance mechanism: the ethanol substrate 
inhibition at high concentration (≤ 10 mM), discussed in Chapter IV. Numerous authors, 
including Krebs, have pointed out this characteristic behavior of alcohol dehydrogenase 
[35, 43, 44]. 
 Figure 10 (B) shows the flux of the reaction catalyzed by aldehyde dehydrogenase 
for the initial conditions (X-axis) used at different ethanol concentrations as shown in 
Table VI. The substrate acetaldehyde is produced from the oxidation of ethanol; as a 
result, the flux of aldehyde dehydrogenase reaction also shows similar trend as alcohol 
dehydrogenase, shown in Figure 10 (A). Figure 10 (C) shows the rate of NADH 
production. Since the change in the redox production rate is also triggered by oxidation of 
ethanol. A similar trend can be observed by means NADH production. 
 Figure 10 (D), (E) and (I) show the net transport of ethanol and acetate from 
blood to tissue. It can be observed that around 60 to 72% of the ethanol uptake by the 
tissue is transported back into the blood as acetate. This is in agreement with 
experimental results of 60 to 73% [53, 69]. Thus, only a small part of acetate is converted 
in to acetyl CoA, while most of acetate is transported back into blood. This characteristic 
is attributed to the fact that the high concentration of NADH produced during ethanol 
metabolism strongly inhibits the enzymes the citric acid cycle: isocitrate dehydrogenase 
and α-ketoglutarate dehydrogenase. [60, 61] 
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Figure 10 Simulation results for the lumped model of liver metabolism with ethanol. 
Weighted average of the flux over the time span 0 to 130 minutes is shown for each 
initial condition mentioned in Table VI for different ethanol concentration. Figure [H] 
show the ratio of flux of acetate released to the ethanol uptake, two horizontal lines show 
the experimental range reported in Huang et al, [69]. Figure [I] show the comparison of 
simulation results (bar) with experimental data (squares) from Krebs et al, [35]. 
 
Figure 10 (F) and (G) show the lactate uptake and the flux of the lactate 
dehydrogenase reaction for different initial conditions shown in Table VI. No change was 
observed in the simulation results of both these fluxes, which actually is contrary to the 
expected results. Since lactate to pyruvate is a reversible reaction converting one NAD
+
 
to one NADH, it is expected that as NADH concentration increases, the lactate 
dehydrogenase reaction is driven towards lactate, converting more pyruvate into lactate.  
Finally, Figure 10 (I) shows the rate of glucose production along with the 
experimental data from Krebs. It can be observed that, even though the experimental 
results and the calculated values are in the same range, the main characteristic of ethanol 
metabolism inhibition of gluconeogenic flux in the fasted state, is actually missing. On 
the contrary, simulation results show a slight increase in the glucose production for the 
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initial ethanol concentration of 1.25, 2.5 and 5 mM.  These apparent shortcoming are 
discussed in the next section.  
 To address these inadequacies we performed manual parameter estimation for the 
two important regulatory steps: reaction catalyzed by the enzyme pyruvate carboxylase 
and conversion of PEP to GAP. The basis for selection of these two reactions is the fact 
that both these reactions appreciably affect gluconeogenic fluxes and are significantly 
influenced by the change in the redox ratios. The intention was to check the effect of 
changes in the kinetic parameters of these regulatory steps on the average rate of glucose 
production. The selection of the kinetic parameters from those two reactions was based 
on their ability to alter sensitivity to redox ratios and the extent of initial approximation in 
the model (those estimated using in vitro data). For the same ethanol concentrations and 
simulation conditions the results are obtained by reducing the kinetic constant values by 
10%, 50% and 90%. Results of this manual parameter estimation are shown in Figure 11 
(A), (B) and (C). It can be observed that decreasing the maximum rate of the pyruvate 
carboxylase reaction, decreases the average glucose production for all initial conditions. 
This effect is significant if the Vmax is decreased to the 10% of its original value. But the 
required characteristic of inhibition of gluconeogenic flux is not obtained. Changes in 
kinetic constants for PEP to GAP reaction show only negligible effects on glucose 
production flux.  
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Figure 11 (A) Effect of change in Vmax_PC on glucose production flux [35]. 
 
Figure 11 (B) Effect of change in Km_pep_gap on glucose production flux [35]. 
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Figure 11 (C) Effect of change in Km_gap_pep on glucose production flux [35]. 
Figure 11 Effect of selected kinetic constants on simulation results of glucose production. 
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5.4 Discussion 
 
The effect of ethanol metabolism on gluconeogenesis has been extensively 
studied in literature. Most of the experiments estimated rates of glucose production from 
various precursors such as alanine, glycerol, dihydroxy acetone, proline, galactose, 
fructose and so forth [36, 39, 40, 57]. The initial lumped model (before addition of 
ethanol metabolism part) was developed and validated considering the perfusion of 
lactate to estimate the rate of glconeogenesis based on data published by Williamson et al 
[67]. Accordingly, the basic aim of this thesis was to investigate the effect of ethanol 
metabolism on gluconeogenesis from lactate. A redox imbalance results from the 
oxidation of ethanol and acetaldehyde. On one hand high concentration of lactate drives 
the LDH reaction towards pyruvate, also converting one NADH into one NAD
+
. On the 
other hand the higher rate of NADH production from alcohol dehydrogenase drives 
pyruvate towards lactate.  Consequently, interpreting which of the control mechanism is 
superior is difficult.   
As a result, starting from lactate only as a substrate source, it becomes very 
difficult to analyze and mathematically demonstrate the effect of ethanol on 
gluconeogenesis. Unfortunately, the data available for our specific application is scarce.  
Our results show almost no change in the lactate dehydrogenase flux and lactate uptake 
with increasing concentration of ethanol. These results can be largely ascribed to the fact 
that the model developed for the lactate dehydrogenase is not sensitive enough to changes 
in redox ratios produced by ethanol metabolism at high lactate concentration (10 mM).  
Additional shortcoming of this effort has been the contradiction of calculated 
results with the experimental results that show inhibited rate of glucose production by 
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ethanol. These numerical results can be attributed to the two steps in gluconeogenic 
pathway: 1) the conversion of pyruvate to phosphoenolpyruvate (PEP) and 2) the 
conversion of phosphoenolpyruvate to glyceraldehyde-3-phosphate (GAP). In the current 
lumped model the conversion of pyruvate to PEP is represented by a lumped reaction 
catalyzed by enzyme pyruvate carboxylase. While this is a reasonable approximation to 
attain simplicity, while keeping the in vivo behavior achievable, in reality pyruvate is 
converted to oxaloacetate by pyruvate carboxylase and oxaloacetate is converted to PEP 
by enzyme PEPCK. Oxaloacetate is also part of citric acid cycle in which it is converted 
to malate by the enzyme malate dehydrogenase. Furthermore, oxaloacetate is the highly 
important part of malate aspartate shuttle, which ultimately is responsible for reoxidation 
of NADH to NAD
+
 through the electron transport chain. Thus it can be concluded that in 
the presence of ethanol it is difficult to lump the reaction for conversion of pyruvate to 
PEP, neglecting further regulation of PEPCK and malate dehydrogenase. 
The reaction catalyzed by pyruvate carboxylase is a highly important step in 
gluconeogenesis. Flux of this reaction is strong function of pyruvate concentration. In the 
presence of ethanol, lactate dehydrogenase reaction is inhibited because of high 
accumulation of NADH and pyruvate produced from lactate dehydrogenase reaction is 
extremely small. As a result, pyruvate carboxylase reaction is inhibited. Furthermore, as 
pyruvate carboxylase reaction is inhibited no oxaloacetate is produced. Thus complete 
malate – aspartate shuttle along with the electron transport chain is stopped. Because of 
all these effects NADH reoxidation is not possible which further increases the inhibition 
of all these reactions and ultimately inhibits the gluconeogenic flux. Figure 12 shows the 
  
reoxidation of NADH through malate dehydrogenase shuttle in the mitochondrial 
compartment with the electron transport chain. 
 
Figure 12. Electron transport chain for reoxidation of NADH with malate dehydrogenase 
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reactions and the oxidative phosphorylation are th
influenced by compartmentation. We have tried to establish a pseudo compartmentation 
using different NAD
+
 and NADH concentrations, but it 
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shuttle[66]. 
is coupled with the oxidation of NADH to 
of PEP to GAP reaction 
an increased flux through PEP to 
H, is shown in Figure
the malate – aspartate shuttle 
e major controlling processes 
was not enough to 
 
 
increases, 
 10 (I).  
ins: blood and 
ate 
correctly 
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simulate in vivo behavior. Establishing a formal mitochondrial compartment for 
appropriate metabolites and reactions along with the regulations of oxidative 
phosphorylation is important to analyze ethanol metabolism. 
  Irrespective of all these inadequacies, this thesis correctly shows the alcohol 
dehydrogenase flux characteristics. The complete lumped model based on the kinetic 
models developed for PFK, FBPase, ADH, ALDH and other enzymes predicts the 
glucose production fluxes within the range of experimental results. This achieves the first 
and foremost important step in establishing a framework for modeling fundamental 
regulation of the liver metabolism. The shortcomings from the model are perceptible and 
can be addressed in future work to bring the model one step closer to reality. 
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CHAPTER VI  
CONCLUSION 
 
Lack of strong metabolic regulation for ethanol is attributed to the fact that 
ethanol is not formed in mammalian tissue and nor it is present in any of the natural 
resources of food. Still the effect of ethanol on metabolic system is severely deteriorating. 
Our attempt has been not only to bring serious attention to these issues, but also to 
present a practical option of using mathematical model to help address these issues in a 
realistic way.  
The kinetic models developed for the substrate cycle through PFK and FBPase are 
acceptable quantitative description of in vitro experimental data and are based on the 
latest findings on the enzymes. Even though the constants of these two models are not 
uniquely estimated, the expected in vivo characteristics of the two enzymes were 
demonstrated in the simulation results. 
The lumped model presented in this thesis predicts the flux of glucose production 
in the correct range as compared to the experimental estimations by Krebs. Two 
important weaknesses can be identified from the results obtained; the model does not 
show expected inhibition of gluconeogenic pathway and the lactate uptake along with the 
lactate dehydrogenase flux remain unchanged for different ethanol concentrations. 
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Kinetic models for lactate dehydrogenase and pyruvate carboxylase can be further 
improved to obtain important regulatory characteristics of these enzymes exhibited at 
high NADH concentration during ethanol metabolism.  It can be easily noticed that most 
of the alterations produced by ethanol are due to the changes in the redox ratios (to some 
extent accumulation of acetyl CoA is also responsible). Consequently the model can be 
further improved to a great extent by introducing a formal compartment for mitochondria 
and kinetics of malate dehydrogenase. This will allow us to account for the differential 
concentration and fluxes of metabolites across the mitochondrial membrane and enforce 
the necessary regulation of redox and the electron transport chain to influence the 
gluconeogenic fluxes. Once this model with mitochondrial compartment is established 
with appropriate validation, it can be used to study effect of ethanol on ketone body 
synthesis and fatty acid production. 
With the recommended improvements to the model the simulated hepatic glucose 
production at different ethanol concentration can be easily related to hypoglycemia 
caused by alcoholism as well as other alcoholic liver disease. Thus importance of this 
effort of modeling ethanol metabolism cannot be overstated.  
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APPENDIX 
 
  
6
9
Table 1. Reaction rate stoichiometry, kinetic expressions, and parameter values used in the model. Definitions: PS=CADP/CATP; 
RSm=CNADH(m)/CNAD(m)
+
;   
For details please refer Chalhoub et al. (2007) 
 
  
Rate Kinetic Expression Parameter Values Method of 
determining 
parameters 
   Parameters common to several 
reactions: 
PSi=0.44 
 
RSi=0.2 
 
 
 Set equal to steady 
state CADP/CATP  
Set equal to steady 
state 
CNADH(m)/CNAD
+
(m)  
A. Reaction Rates 
RGK 
 
GLC + ATP → G6P+ ADP 






++ PSPS
PS
CK
CV
itGLCGKm
tGLCGK
/1/1
/1
_,
_max,  
Vmax,GK =2.19 µmol gww hep
-
1
min
-1
 
 
 
KM,GK =6.25 µmol/gww hep 
Calculated from RGK 
flux (from FBA, 
assuming 30% cycling) 
and steady state GLC 
concentration 
Set equal to steady state 
GLC concentration  
RG6Pase 
 
G6P→GLC 
PGPaseGm
PGPaseG
CK
CV
66,
66max,
+
 
Vmax,G6Pase=3.65 µmol gww hep
-
1
min
-1
 
 
 
Km,G6Pase=0.102 µmol/gww hep 
Calculated from RG6Pase 
flux 
from FBA and steady 
state G6P concentration 
Set equal to steady state 
G6P concentration 
  
7
0
 
RGI 
G6P ↔ F6P 
GIPGm
PG
GIPFm
PF
GIeq
PG
PF
GIPFm
GIPG
K
C
K
C
K
C
C
K
V
,6,
6
,6,
6
,
6
6
,6,
,6max,
1 ++








−
 
Vmax,G6P,GI =32.8 µmol gww hep
-1
min
-1
 
 
 
Km,F6P,GI =0.046 µmol/gww hep 
 
Km,G6P,GI =0.10 µmol/gww hep 
 
Keq,GI=2.5 
Calculated from RGI 
flux from FBA and 
steady state F6P and 
G6P concentrations 
Set equal to steady state 
F6P concentration 
Set equal to steady state 
G6P concentration 
Calculated from  in vivo 
concentrations 
 
 
RFBPase 
 
F1,6BP → F6P 
( )
( ) ( )
( )
( )
( )
( )
FBPaseiAMP
AMP
FBPaseicAMP
cAMP
FBPaseBPiF
BPF
FBPaseBPF
BPF
n
n
FBP
n
FBP
n
nn
n
FBPase
K
C
K
C
K
C
K
C
c
L
V
FBP
fbp
fbp
fbp
fbpfbp
fgbp
,,
,6,2
6,2
,6,1
6,1
max,
;
;;
1
1
1
1
11
1
==
==
++
+
+
++
++
+
δγ
βµ
µ
γ
β
δγβγ
σβ
µµ
 
Vmax,FBPase=20 µmol gww hep
-1
min
-1 
KF1,6BP,FBPase=4.84E-04 µmol/gww hep* 
KicAMP,FBPase=9.23E-03 µmol/gww hep* 
KiF2,6BP,FBPase =1.56E-02 
 µmol/gww hep 
KiAMP,FBPase=0.106 µmol/gww hep 
nFBP=5.52 
LFBP=2.76E+06 
CFBP=0.56 
Calculated from in vitro 
kinetic data 
*modified 10- 20% from 
the original source. 
  
7
1
 
 
RPFK 
 
F6P + ATP  → F1,6BP + 
ADP 
( )
                                                       
                                               
            1
,
,
                                                 
max,
2,
,
2
6,21,6,2
6,2,6,2
1
1
1
2
2
2
2
1
1,6
2
6
2
6








+
+
=








+
+
=
++








++=
⋅+
⋅
=
AMPPFKiAM
AMPPFKiAM
BPFPFKBPiF
BPFPFKBPiF
nnATPn
ATP
APP
PFKPFPFK
PFATPPFK
PFATP
CQK
CK
T
CQK
CK
T
TT
PFKiAT
K
C
T
PFKATP
KCKK
CCK
CC
PFK
V
V
σ
α
 
Vmax,PFK=3.75 µmol gww hep
-1
min
-1
 
KATP,PFK=2.91E-02 µmol/gww hep  
KiATP,PFK=0.058 µmol/gww hep  
KiAMP,PFK=1.16 µmol/gww hep  
K
APP
F6P,PFK=4.0E-04 µmol/gww hep  
KiF2,6BP,PFK=1.7E-02 µmol/gww hep  
α =2.0              σ=3.5 
n1=3.0             n2=3.0 
Q1=100           Q2=50 
 
Calculated from in vitro 
kinetic data. 
 
 
 
RPK 
 
PEP + ADP → PYR + ATP 
 
 
( )
( ) ( )
( ) ( )
( )
PKFBP
FBP
PKiALA
ALA
PKATP
ATP
PKPEP
PEP
n
nn
PKALA
n
PKATP
n
p
n
PK
K
C
K
C
K
C
K
C
L
V
PK
PKPK
PKpk
PK
,,
,,
,
,
1
max,
;
;;
1
11
11
1
==
==
+++
++
++
++
−
φβ
γπ
γπ
φβκ
γκβ
γππ
 
 
Vmax,PK=62.5µmol gww hep
-1
min
-1
 
KPEP,PK=3.2E-02 µmol/gww hep  
KATP,PK=0.435 µmol/gww hep 
KiALA,PK=1.16E-01µmol/gww hep  
KFBP,PK=5.80E-04 µmol/gww hep* 
Lp=1.60E+04 
nPK=3.10 
κΑΤP,PK=2.0  
κALA,PK=0.2   
 
Calculated from in vitro 
kinetic data; modified 
from the original source. 
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2
 
RLDH 
 
LAC + NAD
+
 ↔PYR + 
NADH 
( )
( )
( ) ( )
LDHPYRm
cNADHPYR
LDHLACm
cNADLAC
LDHeq
cNADHPYR
cNADLAC
LDHLACm
LDH
K
CC
K
CC
K
CC
CC
K
V
,,,,
,,,
max,
1 ++








−
+
+
 
Vmax,LDH=195 µmol gww hep
-1
min
-1
 
Km,LAC,LDH=1.43 µmol/gww hep  
 
 
Km,PYR,LDH=4.77E-05 µmol/gww hep  
 
 
 
Keq,LDH=1.1E-04 
in vitro 
Set equal to product of  
steady state LAC and 
NAD
+
(c) 
a
 
concentrations 
Calculated from in vivo 
LDH flux
15
 and steady 
state LAC, PYR,  
NAD
+
(c)
a
, and NADH(c)
b
 
concentrations 
in vitro 
 
RALA→ PYR 
 
ALA + NAD
+ 
→ PYR+ 
NADH 
( )
( )
( ) ( )
ALAPYRm
cNADHPYR
PYRALAm
cNADALA
PYRALAeq
cNADHPYR
cNADALA
PYRALAm
PYRALA
K
CC
K
CC
K
CC
CC
K
V
,,,,
,,,,
,max,
1 ++








−
+
+
 
Vmax,ALA,PYR=300 µmol gww hep
-1
min
-1
 
KmALA,PYR=0.71 µmol/gww hep  
 
 
Km,PYR,ALA=2.4E-07 µmol/ 
gww hep  
 
Keq,ALA,PYR=2.5E-03 
in vitro 
Set equal to product of  
steady state ALA 
 
and 
NAD
+
(c)
a
 concentrations 
Calculated from in vivo 
flux
15 
and steady state 
ALA, NAD
+
(c)
a
  , PYR 
and NADH(c)
b
 
concentrations 
In vitro 
  
 
RPYR
à
PEP 
 
PYR + ATP + GTP  → 
 PEP + ADP + GDP + Pi + 
CO2 
 














+








+
=








+
++








+
PCPC
PC
PC
n
ATP
ADP
PCATPADPi
ATP
PCAcCoAa
n
AcCoA
PCPYRADPi
ADPn
PYR
PCPYR
n
ATP
PCATP
PCPYRADPi
ADP
PC
C
C
K
K
K
C
K
C
C
K
C
K
K
C
V
13
2
1
,,,
,,
,,,
,,
,,,
max,
1
1
1
1
1
1
ϖ
ϖ
Vmax,PC=12.4 µmol gww hep
-1
min
-1
 
KATP,PC=0.034 (µmol/gww hep)
^1.03
  
KPYR,PC=7.1 (µmol/gww hep)
^0.8
  
KiADP,PYR,PC=1.74 µmol/gww hep  
KiADP,ATP,PC=0.521 µmol/gww hep  
Ka,AcCoA,PC=2.28E-05 (µmol/gwwhep)
^1.65
 
n1,PC =1.03 
n2,PC =0.80 
n3,PC  =1.65 
Calculated from in vitro 
kinetic data for pyruvate 
carboxylase 
  
7
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RPEP ↔ GAP 
 
PEP + ATP + NADH↔ 
GAP + ADP + NAD+ 
( )
( )
( ) ( )
PEPGAm
ADPcNADPiGAP
GAPPEPm
ATPcNADHPEP
GAPPEPeq
ADPcNADPiGAP
ATPcNADHPEP
GAPPEPm
GAPPEP
K
CCCC
K
CCC
K
CCCC
CCC
K
V
,,,,
,,,,
,max,
1
+
+
++








−
 
Vmax,PEP,GAP =94.0 µmol gwwhep
-1
min
-1
 
 
Km,PEP,GAP =4.3E-05 µmol/gww hep  
 
Km,GAP,PEP=9.13E-03 µmol/ 
gww hep  
 
 
Keq,PEP,GAP=4166 
In vitro 
Set equal to  product of  
PEP, NADH(c)
b
, and 
ATP concentrations
,
; 
modified during 
parameter estimation 
Calculated from RPEP ↔ 
GAP 
flux from FBA and 
steady state PEP, ATP, 
NAD
+
(c)
a
,    NADH(c)
b
, 
GAP, and ADP 
In vitro  
RGAP↔F1,6BP 
 
GAP↔F1,6BP GAPBPFGAPm
GAPBPFGAP
CK
CV
+6,1,,
6,1,max,
 
Vmax,GAP,F1,6BP = 
4.97 µmol gwwhep
-1
min
-1
 
 
Km,GAP,F1,6BP =0.0194 µmol/gww hep  
Calculated from 
RGAP↔F1,6BP 
flux from FBA and 
steady state GAP 
concentration 
Set equal to steady state 
GAP concentration
57,66
 
 
RPDC 
 
PYR + NAD+ → AcCoA + 
NADH 
( ) ( )PYRPDCmPDC
CoA
AcCoA
PDC
PDC
PYRPDC
CKRS
C
C
PS
CV
+





++





+
2
max,
11 δβ
α
 
Vmax,PDC = 
1.88 µmol gww hep
-1
min
-1
 
KPDC=0.20 µmol/gww hep  
α,PDC = 0.9 
β,PDC = 25;  δ,PDC = 0.50 
Calculated from in vitro 
kinetic data 
RFFA → AcCoA 
 
FFA + 2ATP + 7NAD+ + 
7FAD→ 
8AcCoA + 7NADH + 
7FADH + 
2ADP 
 








+







++ PSPS
PS
RSRS
RS
CK
CV
imi
m
FFAAcCoAFFAm
FFAAcCoAFFA
/1/1
/1
/1/1
/1
,,,,
,max,
 
Vmax,FFA,AcCoA= 
6.76 µmol gww hep
-1
min
-1
 
 
Km,FFA,AcCoA =0.36 µmol/gww hep  
 
Calculated from in vivo 
flux, steady state FFA, 
PS, and RSm 
concentrations 
Set equal to steady state  
FFA concentration 
  
7
4
 
 
 
 
 
 
 
RTG→FFA 
 
 tTGFFATGm
tTGFFATG
CK
CV
,,,
,,max,
+
 
FFATGV ,max,  = 
3.67 µmol gww hep
-1
min
-1 
FFATGmK ,,  =0.0071 µmol/ 
gww hep  
 
Calculated from 
RTG→FFA 
flux from FBA and 
steady state TG,t
 
concentration 
Set equal to steady state   
TG,t
 
concentration 
RGLR_t→GR3P 
 
GLR+ATP→GR3P+ADP 






++ PSPS
PS
CK
CV
itGLRPGRGLRm
tGLRPGRGLR
/1/1
/1
,3,,
,3,max,
 
PGRGLRV 3,max, = 
0.79 µmol gww hep
-1
min
-1
 
 
PGRGLRmK 3,, = 0.125 µmol/ 
gww hep  
Calculated from in vivo 
flux and steady state PS 
and assumed GLR,t 
concentrations.  
Set equal to the assumed 
steady state GLR,t 
concentration 
 
RGR3P↔GAP 
 
GR3P+NAD+↔GAP+NAD
H 
( )
( )
( ) ( )
PGRGAPm
cNADHGAP
GAPPGRm
cNADPGR
GAPPGReq
cNADHGAP
cNADPGR
GAPPGRm
GAPPGR
K
CC
K
CC
K
CC
CC
K
V
3,,,3,
3
,3,
3
,3,
,3max,
1 ++








−
+
++
 
Vmax,GR3P,GAP= 
115 µmol gww hep
-1
min
-1
 
Km,GR3P,GAP=0.47 µmol/gww hep  
 
 
Km,GAP,GR3P=7.06E-07 µmol/gww hep  
 
 
 
Keq,GR3P,GAP=1.3E-04 
in vitro  
Set equal to product of  
steady state GR3P  and 
NAD
+
(c)
a
 concentrations 
Calculated from 
RGR3P↔GAP 
flux from FBA and 
steady state GR3P, 
NAD
+
(c)
a
,    NADH(c)
b
, 
and GAP concentrations 
In vitro  
  
7
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RFA_syn 
 
8AcCoA + 7ATP →  
FFAc16 + 7ADP 
 






++ PSPS
PS
CK
CV
iAcCoAsynFAm
AcCoAsynFA
/1/1
/1
_,
_max,
 
synFAV _max, =2.7 µmol  
gww hep
-1
min
-1
 
 
synFAmK _, =0.13 µmol/gww 
hep  
Calculated from RFA_syn 
flux from FBA and steady 
state AcCoA concentration 
Set equal to the steady state 
AcCoA concentration. 
RTG_f 
 
3FFAc16 + 2ATP + GR3P →  
TG + 2ADP 






++−
−
PSPS
PS
CCK
CCV
iFFAPGRfTGm
FFAPGRfTG
/1/1
/1
3,
3max,  fTG
V −max, =  
0.43 µmol gww hep
-1
min
-1
 
fTGmK −, =0.11 µmol/gww 
hep  
Calculated from RTG_f 
flux from FBA and steady 
state FFA concentration 
Set equal to the product of 
steady state FFA
14
 and 
GR3P
 
concentrations. 
RTCA 
8AcCoA+ADP +3NAD+ + 
FAD→ 
  16CO2 + ATP + 3NADH 
+FADH 








+
−+
+ PSPS
PS
RSRS
RS
CV
imi
m
AcCoATCAmzx
/1/1
/1
)1(
/1/1
/1
,,
, εε
 
Vmax,TCA= 
22.33 µmol gww hep
-1
min
-1
 
 
ε =0.75 
Calculated from in vivo 
flux
 
and steady state 
AcCoA concentration. 
Derived previously.
 
RAcCoA→AcAc 
2AcCoA→AcAc+2Co
A AcCoAAcAcAcCoAm
AcCoAAcAcAcCoA
CK
CV
+_,
_max,
 
AcAcAcCoAV _max, = 
9.28 µmol gww hep
-1
min
-1
 
AcAcAcCoAmK _, =0.124 
µmol/gwwhep  
Calculated from 
RAcCoA→AcAc 
flux from FBA and steady 
state AcCoA concentration 
 
 
 
RBHBdh 
 
AcAc + NADH↔BHB + 
NAD 
 
      
( )
( )
( ) ( )
AcAcBHBm
mNADBHB
BHBAcAcm
mNADHAcAc
BHBdheq
mNADBHB
mNADHAcAc
BHBAcAcm
BHBAcAc
K
CC
K
CC
K
CC
CC
K
V
_,_,
,_,
_max,
1
+
+
++








−
 
BHBAcAcV _max,  = 
60 µmol gww hep
-1
min
-1 
BHBAcAcmK _, =0.0071µmol/ 
gww hep  
AcAcBHBmK _, =0.0059µmol/ 
gww hep  
BHBdheq
K
,
=20 
In vitro  
Set equal to product of  
steady state concentrations 
of AcAc and NADHm 
(assumed = 0.01  µmol 
gww
-1
 hep) 
Calculated from RBHBdh 
flux from FBA and steady 
state substrate 
concentrations 
in vitro 
  
7
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ROxPhos 
 
O2 + 5ADP + 2NADH → 
2H20 + 5ATP +2NAD
+ 
 






+






++ mi
m
iOOxPhosm
OOxPhos
RSRS
RS
PSPS
PS
CK
CV
2
2
,
max,
 
Vmax,OxPhos= 
37.8 µmol gww hep
-1
min
-1
 
 
Km,OxPhos=7.3 µmol/gww hep  
 
Calculated from ROxPhos 
flux from FBA and steady 
state  O2
 
concentration 
Set equal to the steady state  
O2
 
concentration 
Rurea 
2NH4+HCO3+3ATP→ 
urea+2ADP+2Pi+AMP+P
Pi 
 
4,
4max,
NHuream
NHurea
CK
CV
+ 






+ PSPS
PS
i /1/1
/1
 
Vmax,urea=2.57 µmol gww hep
-
1
min
-1
 
 
 
Km,urea=0.70 µmol/gww hep  
Calculated from Rurea flux 
from FBA and steady state 
NH4
+ 7 
concentration 
Set equal to steady state 
NH4
+ 
concentration 
RGlyc
à
G6P 
(Glyc)n à (Glyc)n-1 + 
G6P              
RGlyc
à
G6P=  0.0358 µmol gww hep
-1
min
-1    Set equal to in vivo flux 
B. Transport Rates 
JGLC,b-t,net 
 )(
)(
,,,,
,,,max,
tGlcbGlctbGlcm
tGlcbGlctbGlc
CCK
CCV
++
−
−
−
 
Vmax,Glc,b_t= 
17.8 µmol gww hep
-1
min
-1
 
 
Km,Glc,b_t=5.07 µmol/gww hep 
Calculated from in vivo 
flux and steady state GLC,b
 
concentration 
Set equal to steady state 
GLC,b concentration 
JLAC,b-t,net 
)(
)(
,,,,
,,,max,
tLacbLactbLacm
tLacbLactbLac
CCK
CCV
++
−
−
−
 
Vmax,LAC,b_t= 
22.5 µmol gww hep
-1
min
-1
 
 
Km, LAC,b_t=1.2 µmol/gww hep 
Calculated from in vivo 
flux
 
and  steady state 
LAC,b concentration 
Set equal to steady state 
LAC,b
15
 concentration 
JFFA,b-t,net 
)(
)(
,,,,
,,,max,
tFFAbFFAtbFFAm
tFFAbFFAtbFFA
CCK
CCV
++
−
−
−
 
Vmax,FFA,b_t=4.7 µmol gww hep
-
1
min
-1
 
 
Km,FFA,b_t=0.67µmol/gww hep 
Calculated from in vivo 
flux
 
and steady state  FFA,b 
concentration 
Set equal to steady state  
FFA,b
15
 concentration 
  
7
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JGLR,b-t,net 
)(
)(
,,,,
,,,max,
tGLRbGLRtbGLRm
tGLRbGLRtbGLR
CCK
CCV
++
−
−
−
 
Vmax,GLR,b_t= 
2.53 µmol gww hep
-1
min
-1
 
 
Km,GLR,b_t=0.16 µmol/gww hep 
Calculated from in vivo flux 
and steady state GLR,b
 
concentration 
Set equal to steady state 
GLR,b
 
concentration 
JTG,b-t,net 
)(
)(
,,,,
,,,max,
tTGbTGtbTGm
tTGbTGtbTG
CCK
CCV
++
−
−
−
 
Vmax,TG,b_t= 
0.044 µmol gww hep
-1
min
-1
 
 
Km,TG,b_t=0.4 µmol/gww hep  
Calculated from flux from 
FBA and steady state TG,b
 
concentration 
Set equal to steady state 
TG,b concentration 
(assumed) 
JALA,b-t,net 
)(
)(
,,,,
,,,max,
tALAbALAtbALAm
tALAbALAtbALA
CCK
CCV
++
−
−
−
 
Vmax,ALA,b_t=12 µmol gww hep
-
1
min
-1
 
 
Km,ALA,b_t=0.56 µmol/gww hep 
Calculated from in vivo flux
 
and steady state ALA,b
 
concentration 
Set equal to steady state 
ALA,b
 
concentration 
JBHB,b-t,net 
)(
)(
,,,,
,,,max,
tBHBbBHBtbBHBm
tBHBbBHBtbBHB
CCK
CCV
++
−
−
−
 
Vmax,BHB,b_t= 
2.64 µmol gww hep
-1
min
-1
 
 
Km,BHB,b_t=0.85 µmol/gww hep  
Calculated from in vivo flux  
and steady state BHB,b
 
 
concentration 
Set equal to steady state 
BHB,b
 
 concentration 
Jpyr,b-t,net 
)(
)(
,,,,
,,,max,
tPYRbPYRtbPYRm
tPYRbPYRtbPYR
CCK
CCV
++
−
−
−
 
Vmax,PYR,b_t=8 µmol gww hep
-
1
min
-1
 
 
Km,PYR,b_t=0.062 µmol/gww hep  
Calculated from in vivo flux
 
and steady state PYR,b
 
concentration 
Set equal to steady state 
PYR,b
15 
concentration 
JAcAc,b-t,net 
)(
)(
,,,,
,,,max,
tAcAcbAcActbAcAcm
tAcAcbAcActbAcAc
CCK
CCV
++
−
−
−
 
Vmax,AcAc,b_t= 
34.8125 µmol gww hep
-1
min
-1
 
 
Km,AcAc,b_t=0.7 µmol/gww hep  
Calculated from in vivo flux   
and steady state AcAc,b
  
concentration 
Set equal to steady state 
AcAc,b
  
concentration 
  
7
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Table 2.  Steady state results, at the overnight fasted state, experimental and calculated, with upstream blood concentrations given here: C
*
Glc= 4.6 
mM; 
   
C
*
LAC=1.7 mM ;
      
C
*
PYR=0.12mM; 
   
C
*
FFA=1.5 mM; 
         
C
*
AcAc=0.43 mM; 
      
C
*
BHB= 1.2 mM; 
  
Fblood =6.57 ml/min ; Vtissue=5.25 cm; Vblood 
=1.03
 
cm
3
 .  Reaction rates (Ri) and transport rates (Ji,b-t) are given in Table 1 (+: production rate, -: uptake rate). For details please refer Chalhoub 
et al. (2007) 
 
 
 
 
 
          
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Metabolite Concentrations µmol gww hep-1 Fluxes µmol gww hep-1min-1 
 Calculated Experimental  Calculated Experimental 
Glc,tissue 6.3 4.5-6  JGLC,b-t,net 1.11 1.2-1.9 
Glc,blood 5.55 5.07-5.48 JLAC,b-t,net -1.38 -1.54 
F6P 0.039 0.046  JBHB,b-t,net 1.09 0.93 
F1,6BP 0.0023 0.016 JALA,b-t,net -0.59 -0.64 
G6P 0.087 0.102  JPYR,b-t,net -0.12 -0.14 
glycogen 109 109-175 JFFA,b-t,net -0.87 -0.8 
GAP 0.015 0.021 JGLR,b-t,net -0.96 -0.14 
GR3P 0.25 0.31 GK 0.57  
PEP 0.0061 0.05 G6Pase 1.68  
PYR,blood 0.024 0.062 GI 1.07  
PYR,tissue 0.023 0.059  GAPàF1,6BP 2.15  
LAC,blood 0.59 0.85-1.2 FBPase 1.08  
LAC,tissue 0.46 0.35-0.95 PFK 0.007  
AcAc,blood 1.47 0.68-0.99 PEPàGAP 2.08  
AcAc,tissue 1.61 0.5-0.78 PK 0.0003  5.56  
BHB,blood 2.07 0.85-1.7 PYRàPEP 2.09 3-3.6, 7.9 
BHB,tissue 5.6 2.23 LDH 1.26  
ALA,blood 0.23 0.5 GLRàGR3P 0.099  
ALA,tissue 0.18 0.47 GR3PàGAP 0.06  
AcCoA 0.13 0.13 FAT_syn 0.71  
ATP 3.46 3.43 FFAàAcCoA 0.86  
ATP+ADP+AMP 5.07 3.68-5.2 TG_f 0.11  
NADH(m)/NAD(m)
+
 0.25 0.18 AcCoaàAcAc 4.83  
NADH(c)/NAD(c)
+
 0.0021 0 .0017 OxPhos 8.20  
   TCA 1.37 1.7 
   JTG,b-t,net 0.03  
   PDC 0.0023  
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Table 3.  Initial conditions and input functions used in simulation of the perfused liver. (RFA-endo=rate of endogenous fatty acid  
oxidation, normalized to µmol C16 (palmitate); JFA-b-t = the sum of the uptake rate of FFA and rate of endogenous fatty acid oxidation).   
For details please refer Chalhoub et al. (2007) 
 Lactate 
perfusion 
Initial 
conditions used 
in Eqn. 4 
Saline pre-perfusion; 
 0 < t ≤ 30 
Lactate infusion;  
30 < t ≤ 60  
Lactate + FA;  
60 < t ≤ 90 
 Ci,perfusate (t=0) =0;  
i=Glc, LAC, 
BHB, AcAc 
(saline pre-
perfusion 
contains no 
substrate) 
RFA-endo = 0.105 
µmol gww hep
-1
min
-1
, 
assumed to be equal to  
experimental 
measurements of ketone 
production during this 
period
65
.   
 
RFA-endo = 0.0573  
µmol gww hep
-1
min
-1
, as 
estimated
65
 from ketone 
production.   
 
CLAC,,perfusate = 
10(1-exp(-(t-30)/τ) mM 
(constant LAC 
concentration of 10 mM in 
perfusate); τ is time 
constant for achieving 
change in susbstrate 
concentration, set to 4 min. 
J
*
FA-b-t=  
0.0573+0.27(1-exp(-(t-60) /τ), 
τ=2.5 min; total rate of 0.33 µmol 
gww hep
-1
min
-1
 determined  from 
experimental measurements of 
oleate infusion
65
.  
 
CLAC,,perfusate =10 mM 
 
Pyruvate 
perfusion 
Initial 
conditions used 
in Eqn. 4 
Saline pre-perfusion; 
 0 < t ≤ 30 
Pyruvate infusion;  
30 < t ≤ 90 
Pyruvate + FA;  
90 < t ≤ 120 
 Ci,perfusate (t=0) =0;  
i=Glc, LAC, 
BHB, AcAc, 
PYR 
(saline pre-
perfusion 
contains no 
substrate) 
RFA-endo = 0.105 
µmol gww hep
-1
min
-1
 
RFA-endo =0.0573  
µmol gww hep
-1
min
-1
 
CPYR,,perfusate = 
2(1-exp(-(t-30)/ τ) mM 
(constant PYR 
concentration of 2 mM in 
perfusate); τ=3 min. 
CLAC,,perfusate calculated from 
Eqn. 3.  
J
*
FA-b-t = 
0.0573+0.27(1-exp(-(t-60) / τ), 
τ=2.5 min; experimental FA uptake 
not reported; assumed equal to data 
from lactate perfusion.  
 
CPYR,,perfusate =2 mM 
 
